State of Control and Mutation

Contraindications to the use of drugs: a history of endometrial hyperplasia and expressed liver failure. The main effect of pharmaco-therapeutic effects of drugs: nonsteroidal tryfeniletylenu derivative, binds to estrogen receptors and provides estrohenopodibnyy, anti-estrogenic (or time) effect, depending on the duration of treatment, sex, body-target; toremifene in the treatment of patients with breast cancer in postmenopausal was revealed a moderate reduction Occupational Safety and Health Administration serum cholesterol and LDL; competitively binds to and inhibits estrohenretseptoramy estrohenoposeredkovanu stimulation of DNA synthesis and replication klitynny; high doses estrohennezalezhnyy antitumor effect, antitumor effect in breast cancer mediated anti-estrogenic effect, but other mechanisms (changes in expression of oncogenes, secretion of growth factors, induction of apoptosis and effects on cell cycle kinetics) also have an antitumor effect. 10 mg, 20 mg, 30 mg, 40 mg № 10 (10h1), № 30 (10h3), № 100 (10x10) in blisters. The main effect of pharmaco-therapeutic effects of drugs: synthetic dekapeptyd, similar to the natural hormone that releases gonadotropin and after a short period of stimulation of pituitary gonadotrophic function inhibits gonadotropin secretion followed by inhibition of both female and male steroidogenesis. Pharmacotherapeutic group: L02BA03 - agents used in hormone therapy. Side effects and complications in the use of drugs: the feeling of heat (hot flashes), increased sweating, vaginal bleeding Induction Of Labor discharge, fatigue, nausea, rash, itching in the genital area, fluid retention, dizziness and depression, weight gain, anorexia, vomiting, constipation, shortness of breath, headache, insomnia, shkirnnyy rash, changes in corneal, cataract, deep vein thrombosis, pulmonary embolism, accede to changes in liver enzyme levels, severe liver dysfunction (jaundice) in the presence of metastases in the bones - the development of hypercalcemia in the early treatment ; increased risk of endometrial accede to polyposis, cancer (due to estrogen stimulation of the drug). Method of production of drugs: Table. Other: AR (including anaphylactic shock), peripheral edema, changes in body odor, flu-like c-m blood flow to the skin and upper chest, excessive sweating, swollen lymph nodes (in the first week of treatment), G urinary retention and / or spinal cord compression (in men in the first two weeks of treatment). Dosing and Administration accede to drugs: dosage set individually; breast cancer, endometrial, kidney, soft tissue sarcoma - adults 10-20 mg 2 g / day treatment for signs of transmitting to the regression process and for accede to next 2-3 years. Side effects accede to complications in the use of drugs: nausea, vomiting, redness and dry skin, accede to headache, depression, drowsiness, pain in the bones and place injury (when metastases), itching in the genital area, vaginal bleeding, swelling, alopecia, disturbances view, here thrombocytopenia, phlebitis, fever, skin Sex Hormone-Binding Globulin in rare cases - changes of peripheral blood or increasing the size of the ovaries, very rarely - clouding of cornea and retinal degeneration, women accede to menopause menstrual cycle may accede to irregular or completely closed; recorded cases accede to endometrial cancer with tamoxifen Anti-nuclear Antibody Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy accede to lactation, severe thrombocytopenia, leukopenia, hypercalcemia. Side effects and complications in the use of drugs: swelling, enhanced heart rate, bradycardia, tachycardia, arrhythmia, Mts CH, changes in ECG, BP rising, MI, phlebitis, pulmonary embolism, stroke, thrombosis, transient ischemic attack, changes (increase, decrease or lack of) appetite, taste sensations, dry mouth or Pulmonary Artery Pressure thirst, dysphagia, nausea, vomiting, diarrhea or constipation, bloating, increase or decrease in body weight, increase the activity of "liver" transaminase and alkaline phosphatase, sore breasts, hinekomastopatiya, increased thyroid androhenopodibni effects - virylizatsiya, acne, seborrhea, increased hair growth, voice change, anemia, thrombocytopenia, leukopenia, neutropenia, increased prothrombin and partial tromboplastychnoho-time pain in the bones, arthralgia, myalgia, increasing muscle tone and change in bone density of bone densitometry accede to women as a result of lowering the level of estrogen (after stopping treatment leyprolidu acetate bone density is restored), headache, dizziness, fainting, insomnia, increased irritability, depression, increased fatigue, paresthesia, memory disturbance, hallucinations, hyperesthesia, emotionally lability, personality change, neyrom'yazovi disorders, peripheral neuropathy; psyche - occurrences in patients with suicidal thoughts and attempts, cough, dyspnea, nosebleed, pharyngitis, pleural effusion, fibrous formation in the lungs, infiltrates in the lungs, respiratory disorders, dermatitis, dry skin, itchy skin, rashes, ekhimozy (skin hemorrhages), alopecia, hyperpigmentation, nail changes, women - acne hipertryhoz, conjunctivitis, blurred vision and hearing loss, tinnitus, dysuria, dysmenorrhea, vaginal bleeding, Intravenous Fluids vagina, vaginitis, white, pain in the prostate, testicular atrophy, pain in the testicles, reduced libido, increased blood urea nitrogen, and accede to hypercalcemia, hyperlipidemia (increase in total cholesterol, LDL cholesterol, triglycerides), hyperphosphatemia, hypoglycemia, hyponatremia, hyperuricemia, induration, hyperemia and accede to at the injection site. 20 mg, 60 mg № 30. Dosing and Administration of drugs: estrohenozalezhnyy breast cancer - dosage set individually; standard dose for first-line hormonal oral 60 mg daily, continued, for the treatment of second-line hormonal treatment dose can be increased to 240 mg / day (120 mg 2 g / day). The main effect of pharmaco-therapeutic effects of drugs: nonsteroidal anti-estrogenic substance with a pronounced effect, due to its ability to prevent the absorption of estrogen receptors in specific accede to accede to organs, inhibits estrogen receptors in autogenous and slows the progression of tumors that are stimulated accede to estrogen.